Follistatin-like protein 1 (FSTL1) is a newly characterized protein that can regulate the immune response in various ways. Dendritic cells (DCs) are central to immune regulation. In this study, we explored the impact of FSTL1 on DC activity in nasopharyngeal carcinoma (NPC) patients.
| INTRODUCTION
In China, the highest incidence of nasopharyngeal carcinoma (NPC) occurs in the Guangxi, Guangdong, Hunan, and Fujian provinces.
People between 40 and 50 years of age are at high risk for this type of carcinoma, and the disease is 2 to 3 times more common in men than women. Ninety-eight percent of NPC originates in the nasopharynx and is characterized as a poorly differentiated squamous cell carcinoma. 1 The etiology of NPC involves genetic factors, infection with the Epstein-Barr virus (EBV), and environmental factors. NPC has been specifically associated with race and exhibits familial clustering such that Southern Chinese descendants living abroad still have a high incidence of NPC. cancer, and lung cancer, among others, and inhibits the proliferation and migration of tumor cells instead promoting apoptosis. Therefore, FSTL1 is a newly discovered tumor suppressor gene. [3] [4] [5] [6] Exogenous (TNF-α) and IL-1β secreted by macrophages, and injecting an adenoviral vector encoding FSTL1 in mice induces excessive IL-6, IL-1β, and TNF-α expression in the liver. 8, 9 These data suggest that FSTL1 might also regulate host immunity through a paracrine mechanism. Furthermore, when examining the relationship between FSTL1 and macrophages, it was observed that FSTL1 expression significantly increased in tissue macrophages after LPS injection into mouse footpads, demonstrating that macrophages can respond to FSTL1 at sites of inflammation. In vitro, FSTL1 activates the mitochondrial electron transport chain and increases the production of ATP and IL-1β secretion from monocytes/macrophages. 10 The specific immune function of dendritic cells (DC) in NPC patients is decreased, and DC function has not been reported to be affected by FSTL1 protein. 
| Peripheral blood mononuclear cell separation and DC induction
Before collecting blood, participants were clearly informed such that they understood the study and signed their informed consent. 
| Cell surface molecule expression detected by flow cytometry
On the third and eighth days of culture, CD40, CD80, CD86, and HLA-DR expression on the DC surface was examined for FITC fluorescence by flow cytometry to judge the maturity of the DCs. 
| Experimental groups
Mature DCs were collected and separated into the following 4 groups: (1) NPC patients (mixed cells + FSTL1), (2) 
| DC and lymphocyte coculture
The ratio of 2 types of cells was approximately 1:8, and during coculture, recombinant human interleukin 7 (rhIL-7) (American PeproTech Inc.) was added to a final concentration of 10 mg/mL. Half of the medium was changed every 3 days, and 20 mg/mL IL-7 was added to all of the groups. On the seventh day, new medium containing IL-7 (20 mg/mL) and IL-2 (American PeproTech Inc.) (40 U/mL) was added to all of the groups, which were cocultured in a 5% CO 2 incubator at 37°C. Finally, all of the cells were harvested on the 15th day. 
| Detection of IFN-γ production and TCR expression

| Data analysis
The data were analyzed using SPSS17.0 and GraphPad Prism v. 5 software. Data are shown as the mean ± SEM of at least 3 independent experiments. Significant differences were determined using 2-way analysis of variance and 2-tailed t-tests. A P value <.05 was considered statistically significant.
3 | RESULTS
| Induction and cultivation of DCs
We measured the expression of CD40, CD86, and HLA-DR on the surface of DCs by flow cytometry. On the third day of culture, the respective expression levels were 20.3%, 32.6%, and 30.0%, which increased to 54.3%, 94.8%, and 67.8% on the eighth day of culture (Figure 1 ).
FIGURE 1
On the third day of culture, the DCs were small and exhibited anchorage-dependent growth and slightly altered morphology. On the eighth day of culture, the DC suspension significantly increased, and the cells became large and irregular with branching morphology. CD40, CD86, and HLA-DR expression levels on the DC surface were higher on day 8 than day 3. *P < .05
FIGURE 2 A, The IFN-γ spots for the different groups. There were more spots in the NPC patient group than in the control group. B, IFN-γ levels increased after FSTL1 addition to the healthy control sample 1 group. C, No significant differences were observed between the NPC patients and healthy control sample 1 after FSTL1 addition. D and E, IFN-γ expression was measured by RT-PCR. The fold RQ of the NPC patient group was 2.49, whereas the RQ of the control group was set to 1. *P < .05 and # P > .05
These results suggested that the DCs matured during the induction and cultivation period.
| The number of T lymphocytes producing IFN-γ increased with culture
The ELISpot assay was performed to quantify the number of T lymphocytes producing INF-γ (termed spots). The results showed that the average number of spots for the NPC patient group was 51.00 (31.00-118.00), whereas the control group exhibited only 40.00 spots (11.00-93.00, P < .05) ( Figure 2A) . "At the same time, as shown in Figure 2B , the mean spot number in the mixed cells + FSTL1 healthy control sample 1 group was 72.00 (41.00-104.00), whereas the healthy control sample 2 group showed 59.50 spots (34.33-88.67, P < .05). However, the NPC patient group and healthy control sample 1 values ( Figure 2C) were not significantly different (P > .05).
IFN-γ gene expression was also investigated using RT-PCR ( Figures   2D and 2E) . Comparison of the NPC patient group with the control group revealed an RQ expression quantity ratio of 2.49:1 (P < .05).
These results demonstrate a significant increase in IFN-γ expression after FSTL1 addition to the culture media of mixed cells.
| The number of T lymphocytes expressing TCRs increased
Tetramers were used to detect TCR expression on CD8 + T cells. The increase in TCR expression in the NPC patient group was larger than in the control group; the same results were observed for the control groups ( Figure 3) . Interestingly, these results are in accordance with the detection of INF-γ spots.
| RT-PCR and Western blot for NF-κb and JNK
The gene and protein expression levels of NF-κb and JNK were measured using RT-PCR and Western blot, respectively. NF-κb and JNK expression showed clear changes (P < .05); NF-κb expression was upregulated, whereas JNK expression was downregulated after treatment with FSTL1. There was also an obvious increase in NF-κb expression and a significant decrease in JNK expression in the NPC patient group (P < .05). Interestingly, the Western blot results showed the same trends as the RT-PCR results. These data suggest that NF-κb mRNA and protein expression were upregulated by FSTL1, whereas JNK expression was downregulated ( Figure 4 ).
FIGURE 3 A, The median TCR expression level in the NPC patient group was 2.99% (2.05%-3.82%) compared with 0.99% in the control group (0.33%-2.09%, P < .05). B, Among healthy control samples, these percentages were 3.49% (3.01%-4.00%) and 1.36% (0.13%-1.75%, P < .05) for group 1 and group 2, respectively. 3 Comparison of the NPC patient and healthy control groups showed no statistically significant differences (P > .05). *P < .05 and # P > .05
| DISCUSSION
Here, we report that the activation of DCs and T lymphocytes is weaker in NPC patients compared with healthy individuals ( Figure 2E left 2 bars) based on the lower IFN-γ and TCR expression observed in the NPC patient groups, which means that healthy donors (non-NPC patients) responded better to the LMP and EBV peptides.
Previous work has shown that DCs from patients show decreased functionality compared with those from healthy donors, although they are not different in number or morphology. 22 Angiogenic factors released by head and neck cancer (HNSCC) patients can induce tolerogenic ability in DCs. 23 Upon activation in response to an inflammatory stimulus (exogenous or endogenous), migratory and lymphoid tissue-resident cDCs display a decrease in phagocytic activity. 24 Carcinoma tissue can drive iDCs to differentiate into endothelial-like cells instead of differentiation into mature DCs, thereby preventing antigen presentation functions. 25 Therefore, there are 2 hypotheses regarding the mechanism by which cancer cells avoid immune attack and establish immune evasion. First, during excrescence generation, carcinoma cells alter the microenvironment by modifying their surface FIGURE 4 A, Western blot was performed with antibodies against GAPDH, NF-κb, and JNK. B and C, On the basis of the RQ values from the NPC patient and the control group, NF-κb levels increased to 6.38:1 (P < .05), and JNK mRNA expression decreased to 0.53:1 (P < .05). B and D, NF-κb gene and protein expression levels were upregulated in the NPC patient group. The RQ relative value was 6.38, and the gray value ratio was 5.74, whereas the RQ relative value and the gray value ratio for the control group were 1 and 3.47, respectively. 4 JNK expression was downregulated.
C and E, The RQ expression value was 0.53:1 (P = .00), and the gray value ratio for the NPC patient group was 1.53, whereas the RQ relative value and the gray value ratio for the control group were 1 and 2.25, respectively. *P < .05
antigens. 26, 27 Second, the antigen presentation function of DCs is suppressed, which prevents the activation of T lymphocytes and suppresses the body's immunity. Thus, it is important to understand the antitumor immune mechanisms of DCs and T lymphocytes. 28, 29 FSTL1 has been acknowledged as a novel inflammatory protein that enhances the composition of inflammatory factors in vivo and in vitro. self-peptides/MHC complexes and cytokines. 38 The suppression of immunological functions in NPC patients might occur because of downregulated TCR expression. 39 When tumor antigens stimulate the immune system, the TCR structure changes, and the effectiveness of this strategy is hampered by the generation of mixed TCR heterodimers containing both exogenous and endogenous TCR chains. 40 Introduced TCRα and β chains can potentially assemble with endogenous TCR chains, which not only reduces expression of the desired TCR pair but can also create a new TCR with unknown specificity that can potentially lead to autoimmunity and off-target toxicity. 41, 42 These mechanisms most likely occur in NPC patients, leading to a low recognition rate of functional TCRs, but this still requires further study.
We found that NF-κb expression was increased after FSTL1 addition ( Figures 4B and 4D ). In T lymphocytes, NF-κb not only stimulated gene transcription but also promoted lymphocyte development and differentiation. The activation of NF-κb signaling pathways inhibits the development of carcinomas, especially via the p65 subunit, which plays an important role in p53-mediated apoptosis. Moreover, NF-κb up-regulation enhances T-cell immunity. 43 MFE can increase NK cell and cytotoxic T-lymphocyte activity by activating NF-κb to generate IFN-γ. 44 Medicines can also suppress NF-κb to inhibit the immune response, which leads to carcinoma cell escape. 45 Our results indicated that the addition of FSTL1 downregulated JNK expression, thereby enhancing immune activity ( Figures 4C and 4E) . JNK also plays a critical role in immunity. For example, the absence of JNK was shown to increased T-lymphocyte cell death. 46 Simultaneously, ΔPK could activate JNK protein activity to suppress the expression of IL-10, which is an immunosuppressive factor. 47 On the basis of these results, we believe that FSTL1 plays a critical role in immune regulation by increasing the antigen presentation ability of DCs and T lymphocytes through altering NF-κb and JNK expression.
Recently, antitumor immune therapies have shown significant advantages because of their reduced toxicity to mammalian cells. [48] [49] [50] With the increased development of molecular and cellular technologies, new approaches to treat malignancy will be identified. FSTL1 can inhibit the migration and proliferation of cancer cells and promote apoptosis, which is beneficial for suppressing carcinoma development. 4, 5, 51 FSTL1 can simultaneously regulate immune responses and act as an anti-inflammatory and antineoplastic factor. As a secreted protein, FSTL1 also has the potential to be exploited as a novel antitumor therapeutic. However, some studies have suggested that FSTL1 might stimulate the development of radial gliomas 52 and promote arthritis by regulating IFN-γ1. 3 By contrast, other studies have shown that FSTL1 is a pro-inflammatory molecule that can accelerate the production of other proinflammatory molecules such as IL-6, IL-1β, and TNF-α. 10, 53 This investigation found that DC immunity in NPC patients was augmented by FSTL1. Similarly, TNF-α has been shown to promote the development of immature DCs into mature DCs. 54, 55 Therefore, the mechanism by which FSTL1 expedites the immune ability of DCs should be elucidated from this perspective. Above all, it is important to investigate the mechanism by which FSTL1 affects DCs to provide a basis for new antitumor immunotherapies.
